Click here to get full coverage on sNDA for Aminolevulinic Acid Gel Plus PDT in sBCC Is Submitted to the FDA - OncLive

sNDA for Aminolevulinic Acid Gel Plus PDT in sBCC Is Submitted to the FDA  OncLive

sNDA for Aminolevulinic Acid Gel Plus PDT in sBCC Is Submitted to the FDA - OncLive

Click here to get full coverage on FDA Accepts Furosemide Autoinjector sNDA for Treatment of Edema in Chronic Kidney Disease or Chronic Heart Failure - Pharmacy Times

FDA Accepts Furosemide Autoinjector sNDA for Treatment of Edema in Chronic Kidney Disease or Chronic Heart Failure  Pharmacy Times

FDA Accepts Furosemide Autoinjector sNDA for Treatment of Edema in Chronic Kidney Disease or Chronic Heart Failure - Pharmacy Times

Click here to get full coverage on sNDA for Ameluz-PDT as a Treatment for Superficial Basal Cell Carcinoma Submitted to FDA - HCPLive

sNDA for Ameluz-PDT as a Treatment for Superficial Basal Cell Carcinoma Submitted to FDA  HCPLive

sNDA for Ameluz-PDT as a Treatment for Superficial Basal Cell Carcinoma Submitted to FDA - HCPLive

Click here to get full coverage on FDA accepts MannKind sNDA for autoinjector that treats edema - Drug Delivery Business

FDA accepts MannKind sNDA for autoinjector that treats edema  Drug Delivery Business

FDA accepts MannKind sNDA for autoinjector that treats edema - Drug Delivery Business

Click here to get full coverage on Can SNDA stock sustain double digit ROE - Market Activity Report & Long-Term Safe Investment Plans - Newser

Can SNDA stock sustain double digit ROE - Market Activity Report & Long-Term Safe Investment Plans  Newser

Can SNDA stock sustain double digit ROE - Market Activity Report & Long-Term Safe Investment Plans - Newser

Click here to get full coverage on MannKind Corporation Announces FDA Acceptance of sNDA for FUROSCIX ReadyFlow™ Autoinjector, Targeting Improved Management of Chronic Heart Failure and Kidney Disease - Quiver Quantitative

MannKind Corporation Announces FDA Acceptance of sNDA for FUROSCIX ReadyFlow™ Autoinjector, Targeting Improved Management of Chronic Heart Failure and Kidney Disease  Quiver Quantitative

MannKind Corporation Announces FDA Acceptance of sNDA for FUROSCIX ReadyFlow™ Autoinjector, Targeting Improved Management of Chronic Heart Failure and Kidney Disease - Quiver Quantitative

Click here to get full coverage on Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT - Sahm

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT  Sahm

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT - Sahm

Click here to get full coverage on NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer - 康方生物

NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer  康方生物

NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer - 康方生物

Click here to get full coverage on FDA Accepts sNDA for Furosemide Autoinjector for Chronic Heart Failure and CKD - HCPLive

FDA Accepts sNDA for Furosemide Autoinjector for Chronic Heart Failure and CKD  HCPLive

FDA Accepts sNDA for Furosemide Autoinjector for Chronic Heart Failure and CKD - HCPLive

Click here to get full coverage on Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years - Dermatology Times

Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years  Dermatology Times

Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years - Dermatology Times

Click here to get full coverage on sNDA Submitted for AXS-05 for the Treatment of Alzheimer Disease Agitation - Psychiatric Times

sNDA Submitted for AXS-05 for the Treatment of Alzheimer Disease Agitation  Psychiatric Times

sNDA Submitted for AXS-05 for the Treatment of Alzheimer Disease Agitation - Psychiatric Times

Click here to get full coverage on FDA accepts roflumilast cream 0.3% sNDA to treat plaque psoriasis in children 2 to 5 years - Contemporary Pediatrics

FDA accepts roflumilast cream 0.3% sNDA to treat plaque psoriasis in children 2 to 5 years  Contemporary Pediatrics

FDA accepts roflumilast cream 0.3% sNDA to treat plaque psoriasis in children 2 to 5 years - Contemporary Pediatrics

Click here to get full coverage on FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML - CancerNetwork

FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML  CancerNetwork

FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML - CancerNetwork

Click here to get full coverage on MannKind says FDA accepts for review its sNDA of of FUROSCIX ReadyFlow - TipRanks

MannKind says FDA accepts for review its sNDA of of FUROSCIX ReadyFlow  TipRanks

MannKind says FDA accepts for review its sNDA of of FUROSCIX ReadyFlow - TipRanks

Click here to get full coverage on MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease - GlobeNewswire

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease  GlobeNewswire

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease - GlobeNewswire

Click here to get full coverage on Biofrontera submits sNDA to FDA for skin cancer treatment By Investing.com - Investing.com Nigeria

Biofrontera submits sNDA to FDA for skin cancer treatment By Investing.com  Investing.com Nigeria

Biofrontera submits sNDA to FDA for skin cancer treatment By Investing.com - Investing.com Nigeria

Click here to get full coverage on Responsive Playbooks and the SNDA Inflection - news.stocktradersdaily.com

Responsive Playbooks and the SNDA Inflection  news.stocktradersdaily.com

Responsive Playbooks and the SNDA Inflection - news.stocktradersdaily.com

Click here to get full coverage on FDA Accepts sNDA for Roflumilast Cream 0.3% in Children Ages 2 to 5 with Psoriasis - HCPLive

FDA Accepts sNDA for Roflumilast Cream 0.3% in Children Ages 2 to 5 with Psoriasis  HCPLive

FDA Accepts sNDA for Roflumilast Cream 0.3% in Children Ages 2 to 5 with Psoriasis - HCPLive

Click here to get full coverage on Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC - TipRanks

Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC  TipRanks

Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC - TipRanks

Click here to get full coverage on SNDA agreements in data centre finance: a hybrid approach - Torys LLP

SNDA agreements in data centre finance: a hybrid approach  Torys LLP

SNDA agreements in data centre finance: a hybrid approach - Torys LLP

Click here to get full coverage on Axsome Submits sNDA for AXS-05 to Treat Agitation in Alzheimer Disease - Patient Care Online

Axsome Submits sNDA for AXS-05 to Treat Agitation in Alzheimer Disease  Patient Care Online

Axsome Submits sNDA for AXS-05 to Treat Agitation in Alzheimer Disease - Patient Care Online

Click here to get full coverage on NMPA Accepts sNDA for Frontline Toripalimab Plus Disitamab Vedotin in HER2+ Urothelial Carcinoma - OncLive

NMPA Accepts sNDA for Frontline Toripalimab Plus Disitamab Vedotin in HER2+ Urothelial Carcinoma  OncLive

NMPA Accepts sNDA for Frontline Toripalimab Plus Disitamab Vedotin in HER2+ Urothelial Carcinoma - OncLive

Click here to get full coverage on Sonida Senior Living (SNDA) Soars 14.7%: Is Further Upside Left in the Stock? - Yahoo Finance

Sonida Senior Living (SNDA) Soars 14.7%: Is Further Upside Left in the Stock?  Yahoo Finance

Sonida Senior Living (SNDA) Soars 14.7%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on Arcutis Submits sNDA for Roflumilast Cream 0.3% to Treat Plaque Psoriasis in Patients as Young as 2 - Dermatology Times

Arcutis Submits sNDA for Roflumilast Cream 0.3% to Treat Plaque Psoriasis in Patients as Young as 2  Dermatology Times

Arcutis Submits sNDA for Roflumilast Cream 0.3% to Treat Plaque Psoriasis in Patients as Young as 2 - Dermatology Times

Click here to get full coverage on MannKind (Nasdaq: MNKD) lands FDA sNDA review, PDUFA July 26, 2026 for ReadyFlow - Stock Titan

MannKind (Nasdaq: MNKD) lands FDA sNDA review, PDUFA July 26, 2026 for ReadyFlow  Stock Titan

MannKind (Nasdaq: MNKD) lands FDA sNDA review, PDUFA July 26, 2026 for ReadyFlow - Stock Titan

Click here to get full coverage on Agios planning sNDA on mixed sickle cell data for mitapivat - BioWorld MedTech

Agios planning sNDA on mixed sickle cell data for mitapivat  BioWorld MedTech

Agios planning sNDA on mixed sickle cell data for mitapivat - BioWorld MedTech

Click here to get full coverage on Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL - OncLive

Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL  OncLive

Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL - OncLive

Click here to get full coverage on China’s NMPA Accepts sNDA for Ivonescimab Plus Chemotherapy in Frontline Advanced Squamous NSCLC - OncLive

China’s NMPA Accepts sNDA for Ivonescimab Plus Chemotherapy in Frontline Advanced Squamous NSCLC  OncLive

China’s NMPA Accepts sNDA for Ivonescimab Plus Chemotherapy in Frontline Advanced Squamous NSCLC - OncLive

Click here to get full coverage on FDA Removes Sparsentan (Filspari) Advisory Committee Meeting for FSGS sNDA - HCPLive

FDA Removes Sparsentan (Filspari) Advisory Committee Meeting for FSGS sNDA  HCPLive

FDA Removes Sparsentan (Filspari) Advisory Committee Meeting for FSGS sNDA - HCPLive

Click here to get full coverage on Sonida Senior Living Inc (SNDA) Q3 2025 Earnings Call Highlights: Strong NOI Growth and ... - Yahoo Finance

Sonida Senior Living Inc (SNDA) Q3 2025 Earnings Call Highlights: Strong NOI Growth and ...  Yahoo Finance

Sonida Senior Living Inc (SNDA) Q3 2025 Earnings Call Highlights: Strong NOI Growth and ... - Yahoo Finance

Click here to get full coverage on FDA accepts MannKind’s sNDA for ReadyFlow Autoinjector By Investing.com - Investing.com South Africa

FDA accepts MannKind’s sNDA for ReadyFlow Autoinjector By Investing.com  Investing.com South Africa

FDA accepts MannKind’s sNDA for ReadyFlow Autoinjector By Investing.com - Investing.com South Africa

Click here to get full coverage on With sNDA, Travere Hopes to Expand Use of Sparsentan to FSGS - Docwire News

With sNDA, Travere Hopes to Expand Use of Sparsentan to FSGS  Docwire News

With sNDA, Travere Hopes to Expand Use of Sparsentan to FSGS - Docwire News

Click here to get full coverage on New Analyst Forecast: $SNDA Given $28.0 Price Target - Quiver Quantitative

New Analyst Forecast: $SNDA Given $28.0 Price Target  Quiver Quantitative

New Analyst Forecast: $SNDA Given $28.0 Price Target - Quiver Quantitative

Click here to get full coverage on GSDM Chapter of Student National Dental Association Won Medium-Sized Chapter of the Year - Boston University

GSDM Chapter of Student National Dental Association Won Medium-Sized Chapter of the Year  Boston University

GSDM Chapter of Student National Dental Association Won Medium-Sized Chapter of the Year - Boston University

Click here to get full coverage on AbbVie Submits sNDA to FDA for Venclexta-Acalabrutinib Combo in Frontline CLL - Applied Clinical Trials

AbbVie Submits sNDA to FDA for Venclexta-Acalabrutinib Combo in Frontline CLL  Applied Clinical Trials

AbbVie Submits sNDA to FDA for Venclexta-Acalabrutinib Combo in Frontline CLL - Applied Clinical Trials

Click here to get full coverage on Arcutis Submits sNDA for Roflumilast Cream 0.3% for Psoriasis in Children Aged 2-5 Years - HCPLive

Arcutis Submits sNDA for Roflumilast Cream 0.3% for Psoriasis in Children Aged 2-5 Years  HCPLive

Arcutis Submits sNDA for Roflumilast Cream 0.3% for Psoriasis in Children Aged 2-5 Years - HCPLive

Click here to get full coverage on BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia - Yahoo Finance

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia  Yahoo Finance

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia - Yahoo Finance

Click here to get full coverage on Halper Sadeh LLC Encourages FSUN, CADE, SNDA Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire

Halper Sadeh LLC Encourages FSUN, CADE, SNDA Shareholders to Contact the Firm to Discuss Their Rights  GlobeNewswire

Halper Sadeh LLC Encourages FSUN, CADE, SNDA Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire

Click here to get full coverage on FDA Accepts sNDA for Sotyktu in PsA - Dermatology Times

FDA Accepts sNDA for Sotyktu in PsA  Dermatology Times

FDA Accepts sNDA for Sotyktu in PsA - Dermatology Times

Click here to get full coverage on FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer - CancerNetwork

FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer  CancerNetwork

FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer - CancerNetwork

Click here to get full coverage on After Leaping 27% Sonida Senior Living, Inc. (NYSE:SNDA) Shares Are Not Flying Under The Radar - simplywall.st

After Leaping 27% Sonida Senior Living, Inc. (NYSE:SNDA) Shares Are Not Flying Under The Radar  simplywall.st

After Leaping 27% Sonida Senior Living, Inc. (NYSE:SNDA) Shares Are Not Flying Under The Radar - simplywall.st

Click here to get full coverage on sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL - CancerNetwork

sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL  CancerNetwork

sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL - CancerNetwork

Click here to get full coverage on FDA Accepts Pegcetacoplan (Empaveli) sNDA for C3G, IC-MPGN - HCPLive

FDA Accepts Pegcetacoplan (Empaveli) sNDA for C3G, IC-MPGN  HCPLive

FDA Accepts Pegcetacoplan (Empaveli) sNDA for C3G, IC-MPGN - HCPLive

Click here to get full coverage on Travere Therapeutics Submits sNDA for Sparsentan (Filspari) in FSGS - HCPLive

Travere Therapeutics Submits sNDA for Sparsentan (Filspari) in FSGS  HCPLive

Travere Therapeutics Submits sNDA for Sparsentan (Filspari) in FSGS - HCPLive

Click here to get full coverage on sNDA Submitted in Japan for T-DXd Plus Pertuzumab in HER2+ Advanced Breast Cancer - OncLive

sNDA Submitted in Japan for T-DXd Plus Pertuzumab in HER2+ Advanced Breast Cancer  OncLive

sNDA Submitted in Japan for T-DXd Plus Pertuzumab in HER2+ Advanced Breast Cancer - OncLive

Click here to get full coverage on J&J Submits sNDA to FDA for Lumateperone (CAPLYTA) to Prevent Schizophrenia Relapse - HCPLive

J&J Submits sNDA to FDA for Lumateperone (CAPLYTA) to Prevent Schizophrenia Relapse  HCPLive

J&J Submits sNDA to FDA for Lumateperone (CAPLYTA) to Prevent Schizophrenia Relapse - HCPLive

Click here to get full coverage on Sonida (SNDA) Q3 2025 Earnings Call Transcript - The Motley Fool

Sonida (SNDA) Q3 2025 Earnings Call Transcript  The Motley Fool

Sonida (SNDA) Q3 2025 Earnings Call Transcript - The Motley Fool

Click here to get full coverage on BXCL501 for Agitation Associated With Bipolar Disorders or Schizophrenia: Positive Pre-sNDA Meeting With FDA - Psychiatric Times

BXCL501 for Agitation Associated With Bipolar Disorders or Schizophrenia: Positive Pre-sNDA Meeting With FDA  Psychiatric Times

BXCL501 for Agitation Associated With Bipolar Disorders or Schizophrenia: Positive Pre-sNDA Meeting With FDA - Psychiatric Times

Click here to get full coverage on Biofrontera submits sNDA to FDA for skin cancer treatment By Investing.com - Investing.com India

Biofrontera submits sNDA to FDA for skin cancer treatment By Investing.com  Investing.com India

Biofrontera submits sNDA to FDA for skin cancer treatment By Investing.com - Investing.com India

Click here to get full coverage on Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity - GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity  GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity - GlobeNewswire

Click here to get full coverage on Halper Sadeh LLC Encourages FRGE, SNDA, GDEN Shareholders to Contact the Firm to Discuss Their Rights - PR Newswire

Halper Sadeh LLC Encourages FRGE, SNDA, GDEN Shareholders to Contact the Firm to Discuss Their Rights  PR Newswire

Halper Sadeh LLC Encourages FRGE, SNDA, GDEN Shareholders to Contact the Firm to Discuss Their Rights - PR Newswire

Click here to get full coverage on FDA Accepts sNDA for Risperidone Extended-Release Injectable Suspension for Bipolar I Disorder - HCPLive

FDA Accepts sNDA for Risperidone Extended-Release Injectable Suspension for Bipolar I Disorder  HCPLive

FDA Accepts sNDA for Risperidone Extended-Release Injectable Suspension for Bipolar I Disorder - HCPLive

Click here to get full coverage on Arcutis Zoryve cream sNDA accepted by FDA for pediatric plaque psoriasis - Seeking Alpha

Arcutis Zoryve cream sNDA accepted by FDA for pediatric plaque psoriasis  Seeking Alpha

Arcutis Zoryve cream sNDA accepted by FDA for pediatric plaque psoriasis - Seeking Alpha

Click here to get full coverage on FDA Accepts Sparsentan (Filspari) sNDA for Focal Segmental Glomerulosclerosis - HCPLive

FDA Accepts Sparsentan (Filspari) sNDA for Focal Segmental Glomerulosclerosis  HCPLive

FDA Accepts Sparsentan (Filspari) sNDA for Focal Segmental Glomerulosclerosis - HCPLive

Click here to get full coverage on Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - Yahoo Finance

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia  Yahoo Finance

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - Yahoo Finance

Click here to get full coverage on SNDA Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Sonida Senior Living, Inc. is Fair to Shareholders - Business Wire

SNDA Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Sonida Senior Living, Inc. is Fair to Shareholders  Business Wire

SNDA Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Sonida Senior Living, Inc. is Fair to Shareholders - Business Wire

Click here to get full coverage on China’s NMPA Accepts sNDA for Repotrectinib for NTRK+ Solid Tumors - OncLive

China’s NMPA Accepts sNDA for Repotrectinib for NTRK+ Solid Tumors  OncLive

China’s NMPA Accepts sNDA for Repotrectinib for NTRK+ Solid Tumors - OncLive

Click here to get full coverage on BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia  GlobeNewswire

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire

Click here to get full coverage on Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML - OncLive

Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML  OncLive

Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML - OncLive

Click here to get full coverage on Sonida Senior Living (NYSE:SNDA) swells 15% this week, taking five-year gains to 240% - simplywall.st

Sonida Senior Living (NYSE:SNDA) swells 15% this week, taking five-year gains to 240%  simplywall.st

Sonida Senior Living (NYSE:SNDA) swells 15% this week, taking five-year gains to 240% - simplywall.st

Click here to get full coverage on Apellis announces FDA priority review for Empaveli sNDA - Pharmaceutical Technology

Apellis announces FDA priority review for Empaveli sNDA  Pharmaceutical Technology

Apellis announces FDA priority review for Empaveli sNDA - Pharmaceutical Technology

Click here to get full coverage on Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer (AXSM) - Seeking Alpha

Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer (AXSM)  Seeking Alpha

Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer (AXSM) - Seeking Alpha

Click here to get full coverage on Halper Sadeh LLC Encourages FRGE, SNDA, GDEN Shareholders to Contact the Firm to Discuss Their Rights - Sahm

Halper Sadeh LLC Encourages FRGE, SNDA, GDEN Shareholders to Contact the Firm to Discuss Their Rights  Sahm

Halper Sadeh LLC Encourages FRGE, SNDA, GDEN Shareholders to Contact the Firm to Discuss Their Rights - Sahm

Click here to get full coverage on FDA slaps CRL on Otsuka and Lundbeck’s Rexulti sNDA - The Pharma Letter

FDA slaps CRL on Otsuka and Lundbeck’s Rexulti sNDA  The Pharma Letter

FDA slaps CRL on Otsuka and Lundbeck’s Rexulti sNDA - The Pharma Letter

Click here to get full coverage on FDA Accepts Finerenone sNDA for Heart Failure, Grants Priority Review - HCPLive

FDA Accepts Finerenone sNDA for Heart Failure, Grants Priority Review  HCPLive

FDA Accepts Finerenone sNDA for Heart Failure, Grants Priority Review - HCPLive

Click here to get full coverage on Arcutis Biotherapeutics announces FDA acceptance of sNDA for ZORYVE - TipRanks

Arcutis Biotherapeutics announces FDA acceptance of sNDA for ZORYVE  TipRanks

Arcutis Biotherapeutics announces FDA acceptance of sNDA for ZORYVE - TipRanks

Click here to get full coverage on sNDA for Sotyktu accepted for FDA review - The Pharma Letter

sNDA for Sotyktu accepted for FDA review  The Pharma Letter

SNDA

Price Chart

Key Statistics

Technicals

About SNDA

Latest News

sNDA for Aminolevulinic Acid Gel Plus PDT in sBCC Is Submitted to the FDA - OncLive

FDA Accepts Furosemide Autoinjector sNDA for Treatment of Edema in Chronic Kidney Disease or Chronic Heart Failure - Pharmacy Times

sNDA for Ameluz-PDT as a Treatment for Superficial Basal Cell Carcinoma Submitted to FDA - HCPLive

Advanced Charts

Top Gainers

Top Losers